Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9197031 | 0.71 | GAA (0.33) | GAAMAPTIDO1L3MBTL1 | |
| SCHEMBL7606328 | 0.67 | KDM4E (0.33) | GAAMAPT | |
| SCHEMBL9099526 | 0.67 | ALDH1A1 (0.35) | GAAMAPTALOX15ALDH1A1 | |
| SCHEMBL582683 | 0.67 | — | — | |
| SCHEMBL19400 | 0.67 | — | — | |
| SCHEMBL10648460 | 0.65 | NOX1 (0.46) | GAAMEN1KMT2AMAPTNOX1 | |
| SCHEMBL7172665 | 0.64 | GAA (0.39) | GAAMEN1KMT2AMAPTNOX1 | |
| SCHEMBL57942 | 0.64 | — | — | |
| SCHEMBL155144 | 0.62 | GAA (0.48) | GAAMEN1KMT2AMAPTNOX1 | |
| SCHEMBL2828423 | 0.61 | GAA (0.52) | GAAMEN1KMT2AMAPTNOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 415 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551999-B2 | Heterocyclic compound and pharmaceutical composition thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | claimed |
| US-8551981-B2 | Furo[3,2-d]pyrimidine compounds | ABBVIE INC. (US) | 2013-10-08 | — | — | US | claimed |
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | claimed |
| EP-2163245-A1 | Renin inhibitors for the treatment of psoriasis | Novartis Ag (CH) | 2010-03-17 | — | — | EP | claimed |
| US-20090270380-A1 | 3,4,5-Substituted Piperidines as Renin Inhibitors | NOVARTIS AG (CH) | 2009-10-29 | — | — | US | claimed |
| US-20090093475-A1 | Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-04-09 | — | — | US | claimed |
| EP-2044071-A1 | OOXO-SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINES, PRODUCTION AND USE THEREOF AS DRUGS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-08 | — | — | EP | claimed |
| US-20090029981-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES | NOVARTIS AG (CH) | 2009-01-29 | — | — | US | claimed |
| EP-2018862-A1 | Substituted piperidines as therapeutic compounds | Speedel Experimenta AG (CH) | 2009-01-28 | — | — | EP | claimed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | claimed |
| WO-1997003070-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES HAVING CGMP-PHOSPHODISTERASE INHIBITING ACTIVITY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-01-30 | — | — | WO | claimed |
| EP-0751944-A1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1997-01-08 | — | — | EP | claimed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | claimed |
| EP-0462813-B1 | Bicyclic pyran derivatives and their use as inhibitors of 5-lipoxygenase | ZENECA LTD (GB) | 1995-10-25 | — | — | EP | claimed |
| WO-1995026347-A1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1995-10-05 | — | — | WO | claimed |
| US-5321025-A | Inhibitors of 5-lipoxygenase | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-06-14 | — | — | US | claimed |
| EP-0600092-A1 | THIAZOLE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-08 | — | — | EP | claimed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | claimed |
| EP-0513387-A1 | ACTIVE OXYGEN INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-19 | — | — | EP | claimed |
| EP-0462813-A2 | Bicyclic pyran derivatives and their use as inhibitors of 5-lipoxygenase | ZENECA LIMITED (GB) | 1991-12-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093475-A1 | Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals | CDK2, CDK1, MAP4K2 | GAA 1976/4885MEN1 1241/4885KMT2A 1579/4885 |
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | GAA 92/4885MEN1 2817/4885KMT2A 3839/4885 |
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | CDK2, DPYD, CDK3 | GAA 2807/4885MEN1 1866/4885KMT2A 3528/4885 |
| US-20090270380-A1 | 3,4,5-Substituted Piperidines as Renin Inhibitors | REN, AGTR1, AGTR2 | GAA 317/4885MEN1 2715/4885KMT2A 3683/4885 |
| US-20090029981-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES | REN, AGTR2, ACE | GAA 505/4885MEN1 3428/4885KMT2A 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.